The role of unacylated ghrelin on age-associated progressive muscle weakness and cachexia elicited by cancer
非酰化生长素释放肽对年龄相关的进行性肌肉无力和癌症引起的恶病质的作用
基本信息
- 批准号:10097947
- 负责人:
- 金额:$ 9.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-15 至 2022-01-31
- 项目状态:已结题
- 来源:
- 关键词:ActomyosinAcuteAdultAffectAgeAgingAnimalsAtrophicBindingBiological AssayBiologyBrainC26 tumorCachexiaCalciumCancer Cell GrowthCancer ModelCellsChronicClinical TrialsCoculture TechniquesColon CarcinomaColorectal CancerCyclic AMP-Dependent Protein KinasesDataDegenerative DisorderDenervationEnsureFRAP1 geneFastingFiberFoundationsFunctional disorderGHS-R1aGenerationsGeneticGlucocorticoidsGoalsGrantHollyHormonesHumanImpairmentIncubatedIndividualInflammationInflammatoryInsulin-Like Growth Factor IInterferon Type IIInterventionLaboratoriesLeadLearningMalignant Epithelial CellMalignant NeoplasmsMeasuresMedical ResearchMentorsMentorshipMicrofilamentsMitochondriaModelingModificationMolecularMolecular BiologyMonitorMusMuscleMuscle FibersMuscle WeaknessMuscle functionMuscular AtrophyMyoblastsMyopathyNerveNerve DegenerationNeuronsObesityOklahomaOxidation-ReductionOxidative StressPRKCA genePathologicPathway interactionsPharmacologyPhasePhosphorylationPhysiologicalPhysiologyPostdoctoral FellowPrincipal InvestigatorProtein BiosynthesisProtein KinaseProteinsQuality of lifeResearchRoleSafetySecureSignal TransductionSkeletal MuscleSomatotropinTNF geneTechniquesTestingThinnessTrainingTranslationsWasting SyndromeWild Type Mousebasecancer cachexiacancer cellcareercareer developmentclinical candidateclinically significantcytokineeffective interventionenergy balanceexperienceexperimental studyghrelinhealthspanimproved functioningin vivoincreased appetiteinnovationlean body massmiddle agemotor neuron functionmuscle agingmuscle formnerve supplyneurogenesisnovelprecursor cellpreventprotein degradationreceptorreduced muscle masssarcopeniaskeletal muscle wastingskeletal muscle weaknessskillssuccesssynthetic peptidesystemic inflammatory responseuptakewasting
项目摘要
Project Summary/Abstract
Skeletal muscle weakness is a hallmark of aging and cancer cachexia that significantly affect individual
healthspans and quality of life. Despite the clinical significance, no pharmacological therapies are currently
available to mitigate muscle atrophy and weakness. The goal of this project is to test the ability of a novel and
promising pharmacological intervention, unacylated ghrelin, to delay skeletal muscle weakness and loss
of muscle mass in aging and in cancer cachexia. Ghrelin is a hormone that increases appetite when the
acylated ghrelin (AG) binds to its receptor in the brain, growth hormone secretagogue receptor-1a (GHSR1a).
An acute rise in AG increases lean mass in wasting conditions, but a concurrent increase in adiposity and
decreased sensitivity in GHSR1a receptor lead to atrophy and contractile dysfunction. In contrast, recent studies
show a direct beneficial effect of the unacylated form of ghrelin (UnAG) on muscle, independent of GHSR1a
activation. Incubating myoblast with UnAG increases differentiation and fusion into myotubes, and inhibited
glucocorticoid-induced muscle atrophy and proteolytic markers. During a 2-day fasting and 14-day denervation,
a chronic increase in circulating UnAG using a genetic modification prevented skeletal muscle atrophy
independent of activation of the growth hormone/IGF-1 axis via GHSR1a. The goal of this proposal is to test the
ability of UnAG to mitigate loss of muscle mass and weakness in two distinct degenerative conditions-sarcopenia
and cancer cachexia. The following aims are proposed: Aim 1: To determine whether UnAG prevents neurogenic
atrophy with aging by altering rates of protein synthesis and degradation in muscle. Aim 2: To determine whether
UnAG prevents contractile dysfunction with aging through modulations of calcium handling and sensitivity. Aim
3: To determine whether UnAG prevents a rapid wasting and contractile dysfunction in cancer cachexia. In order
to understand the molecular mechanisms of UnAG on skeletal muscle cells, I will learn and perform state-of-the-
art molecular biology and integrative physiology techniques to assess in vivo protein turnover rate and calcium
handling and sensitivity of myofilaments (intracellular calcium transient and uptake). If my results support the
hypothesis, clinical trials may be warranted. UnAG and its synthetic peptides have excellent safety profiles in
humans and animals with null association to cancer cell growth.
The principal investigator (PI) of this grant is a postdoctoral fellow under the mentorship of Dr. Van Remmen
at Oklahoma Medical Research Foundation. The PI will learn state-of-the-art molecular biology and integrative
physiology techniques from his co-mentors Drs. Benjamin Miller and Susan Brooks, respectively. These
techniques will be critical in the PI’s independent laboratory and boost his scientific career. The PI’s primary
mentor, Dr. Holly Van Remmen, will train him the expertise in redox biology and share her experience and
success in aging research. Dr. Van Remmen will monitor overall progress of the project and the PI’s career
development during the mentored phase and ensure his secure transition toward independence.
项目摘要/摘要
骨骼肌无力是衰老和癌症恶病质的标志,严重影响了个体
健康范围和生活质量。尽管具有临床意义,但目前尚无药理疗法
可用于减轻肌肉萎缩和无力。该项目的目的是测试小说的能力和
有希望的药物干预措施,未酰化的生长素素,延迟骨骼肌肉无力和损失
衰老和癌症恶病质中的肌肉质量。 Ghrelin是一匹马,可以增加食欲
酰化的生长素蛋白(Ag)与其在大脑中的受体结合,生长的Horsene secretagogue受体-1A(GHSR1A)。
Ag急性增加会增加浪费条件下的瘦质量,但同时增加肥胖和增加
GHSR1A受体的敏感性降低导致萎缩和收缩功能障碍。相反,最近的研究
在肌肉中表现出非囊化形式的生长素(unag)的直接有益作用,与GHSR1A无关
激活。与Unag一起孵育肌细胞会增加分化和融合到肌管中,并抑制
糖皮质激素引起的肌肉萎缩和蛋白水解标记。在2天的禁食和14天的改造中,
使用遗传修饰预防骨骼肌萎缩的慢性增加循环统一
独立于通过GHSR1A激活生长马/IGF-1轴。该提议的目的是测试
在两个不同的退化性疾病中,脱离肌肉质量和无力的能力 - 肌肉减少症
和癌症恶病质。提出了以下目的:目标1:确定Unag是否阻止神经源性
通过改变蛋白质合成速率和肌肉降解的衰老,萎缩。目标2:确定是否
通过钙处理和敏感性调节,Unag可防止收缩功能障碍,并通过衰老而衰老。目的
3:确定Unag是否可以防止癌症恶病质中的快速浪费和收缩功能障碍。为了
为了了解骨骼肌细胞上Unag的分子机制,我将学习并执行最新的
ART分子生物学和综合生理技术评估体内蛋白质周转率和钙
肌膜的处理和灵敏度(细胞内钙瞬态和摄取)。如果我的结果支持
假设,可能需要进行临床试验。 Unag及其合成Pepperides具有出色的安全性。
人类和动物与癌细胞生长无效的动物。
该赠款的首席研究员(PI)是范·雷曼(Van Remmen)博士的心态下的博士后研究员
在俄克拉荷马州医学研究基金会。 PI将学习最先进的分子生物学和综合性
他的联合主管Drs的生理技术。本杰明·米勒(Benjamin Miller)和苏珊·布鲁克斯(Susan Brooks)。这些
技术在PI的独立实验室中至关重要,并提高他的科学生涯。 PI的主要
导师霍莉·范·雷曼(Holly Van Remmen)博士将培训他在氧化还原生物学方面的专业知识,并分享她的经验和
衰老研究的成功。 Van Remmen博士将监控该项目的整体进展和PI的职业
在修补阶段的发展,并确保他向独立的安全过渡。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Neuron-specific deletion of CuZnSOD leads to an advanced sarcopenic phenotype in older mice.
- DOI:10.1111/acel.13225
- 发表时间:2020-10
- 期刊:
- 影响因子:7.8
- 作者:Bhaskaran S;Pollock N;C Macpherson P;Ahn B;Piekarz KM;Staunton CA;Brown JL;Qaisar R;Vasilaki A;Richardson A;McArdle A;Jackson MJ;Brooks SV;Van Remmen H
- 通讯作者:Van Remmen H
Comparative Efficacy of Angiotensin II Type 1 Receptor Blockers Against Ventilator-Induced Diaphragm Dysfunction in Rats.
- DOI:10.1111/cts.12916
- 发表时间:2021-03
- 期刊:
- 影响因子:0
- 作者:Hall SE;Ahn B;Smuder AJ;Morton AB;Hinkley JM;Wiggs MP;Sollanek KJ;Hyatt H;Powers SK
- 通讯作者:Powers SK
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bumsoo Ahn其他文献
Bumsoo Ahn的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bumsoo Ahn', 18)}}的其他基金
The role of unacylated ghrelin on age-associated progressive muscle weakness and cachexia elicited by cancer
非酰化生长素释放肽对年龄相关的进行性肌肉无力和癌症引起的恶病质的作用
- 批准号:
10545896 - 财政年份:2020
- 资助金额:
$ 9.6万 - 项目类别:
The role of unacylated ghrelin on age-associated progressive muscle weakness and cachexia elicited by cancer
非酰化生长素释放肽对年龄相关的进行性肌肉无力和癌症引起的恶病质的作用
- 批准号:
10609936 - 财政年份:2020
- 资助金额:
$ 9.6万 - 项目类别:
The role of unacylated ghrelin on age-associated progressive muscle weakness and cachexia elicited by cancer
非酰化生长素释放肽对年龄相关的进行性肌肉无力和癌症引起的恶病质的作用
- 批准号:
9892798 - 财政年份:2020
- 资助金额:
$ 9.6万 - 项目类别:
相似国自然基金
去泛素化酶USP5调控P53通路在伴E2A-PBX1成人ALL的致病机制研究
- 批准号:81900151
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
核基质结合区蛋白SATB1调控CCR7抑制急性T淋巴细胞白血病中枢浸润的作用与机制
- 批准号:81870113
- 批准年份:2018
- 资助金额:55.0 万元
- 项目类别:面上项目
成人及儿童急性淋巴细胞白血病的基因组转录组生物信息学分析方法建立及数据分析
- 批准号:81570122
- 批准年份:2015
- 资助金额:60.0 万元
- 项目类别:面上项目
NR3C1基因突变在成人急性淋巴细胞白血病耐药与复发中的作用与机制研究
- 批准号:81470309
- 批准年份:2014
- 资助金额:75.0 万元
- 项目类别:面上项目
儿童和成人急性T淋巴细胞白血病中miRNA和转录因子共调控网络的差异性研究
- 批准号:31270885
- 批准年份:2012
- 资助金额:80.0 万元
- 项目类别:面上项目
相似海外基金
Molecular and Cell Biological Foundations of Proteostress-Induced Neuronal Extrusion
蛋白质应激诱导的神经元挤压的分子和细胞生物学基础
- 批准号:
10753902 - 财政年份:2023
- 资助金额:
$ 9.6万 - 项目类别:
The role of unacylated ghrelin on age-associated progressive muscle weakness and cachexia elicited by cancer
非酰化生长素释放肽对年龄相关的进行性肌肉无力和癌症引起的恶病质的作用
- 批准号:
10545896 - 财政年份:2020
- 资助金额:
$ 9.6万 - 项目类别: